

**REMARKS**

The Examiner has indicated that claims 1-17 and [2]0-22, directed to compounds and methods of synthesis, will be examined in this application together with the subject matter of one of:

Group I: claims 18 and 19 in part - directed to a method for regulating the immune system and treatment of allergies;

Group II: claim 19 in part - directed to a method for treatment of viral disorders; and

Group III: claim 19 in part - directed to a method for treatment of cancers.

**Applicants hereby elect, with traverse, the subject matter of Group I for prosecution in this application.**

Applicants submit that separation of the methods of treatment is better addressed by election of species practice, whereby should the subject matter elected (regulation of immune response and treatment of allergy) is found allowable, the other methods of treatment would be subsequently examined.

Should there be any outstanding matters that need to be resolved in the present application, the Examiner is respectfully requested to contact Mark J. Nuell, Ph.D. (Reg. No. 36,623 ) at the telephone number of the undersigned below, to conduct an interview in an effort to expedite prosecution in connection with the present application.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37.C.F.R. §§1.16 or 1.14; particularly, extension of time fees.

Dated: May 4, 2009

Respectfully submitted,

By 

Mark J. Nuell

Registration No.: 36,623

BIRCH, STEWART, KOLASCH & BIRCH, LLP

12770 High Bluff Drive, Suite 260

San Diego, CA 92130

(858) 792-8855

Attorney for Applicant